In this case involving contaminated doses of an antiviral medication, the defendants were immune from liability under the federal Public Readiness and Preparedness Act because they did not engage in “willful misconduct” by manufacturing or administering the contaminated drug to the plaintiffs, the Michigan Court of Appeals has ruled.

A trial court correctly denied a patient advocate’s request for an order directing that ivermectin be administered to her father, who was hospitalized with COVID-19.